New hope for rare blood cancer: zanubrutinib trial targets untreated patients
NCT ID NCT07169331
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the drug zanubrutinib (Brukinsa) in 18 Chinese adults who have Waldenström macroglobulinemia but have not yet received any treatment. The goal is to see how well the drug controls the disease and to check for side effects. Participants take zanubrutinib by mouth, and the study will measure tumor shrinkage and response rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanubrutinib (Brukinsa)
What this could lead to
If successful, this study could confirm zanubrutinib as a safe and effective first treatment for Chinese patients with Waldenström macroglobulinemia, helping control the disease.
What could go wrong
This is a small, single-arm study with only 18 participants, so results may not apply broadly. As a phase 4 trial, the drug is already approved, but side effects or lack of strong response are still possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM'S MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Hebei University
RECRUITINGBaoding, Hebei, 071000, China
-
Nanfang Hospital, Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510515, China
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
-
Sun Yat Sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310003, China
-
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430022, China
-
Xiangya Hospital of Central South University
RECRUITINGChangsha, Hunan, 410008, China
-
Yichang Central Peoples Hospital
RECRUITINGYichang, Hubei, 443003, China